Clinical Trials

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Study ID
Bristol-Myers Squibb CA209-039

NCT Number
NCT01592370 (Click on the NCT number for more information about the trial)

Research Study Number

Principle Investigator
Dr. Martin Gutierrez


Bristol-Myers Squibb

Other protocol defined inclusion/exclusion criteria could apply If you are a physician and would like more details about this study, please contact us at

Apply Now